Literature DB >> 26813344

IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation.

S E Russell1,2, R M Horan1,2, A M Stefanska1,2, A Carey2, G Leon1,2, M Aguilera3, D Statovci3, T Moran1,2, P G Fallon1,2, F Shanahan3, E K Brint4, S Melgar3, S Hussey2,5, P T Walsh1,2.   

Abstract

A role for the IL-36 family of cytokines has been identified in the pathogenesis of psoriasis. Although significant mechanistic overlap can exist between psoriasis and inflammatory bowel disease (IBD), to date there have been no reports investigating the IL-36 family in gastrointestinal inflammation. Here we demonstrate that expression levels of IL-36α are specifically elevated in the colonic mucosa of ulcerative colitis patients. This elevated expression is mirrored in the inflamed colonic mucosa of mice, wherein IL-36 receptor deficiency confirmed this pathway as a mediator of mucosal inflammation. Il36r-/- mice exhibited reduced disease severity in an acute DSS-induced model of colitis in association with decreased innate inflammatory cell infiltration to the colon lamina propria. Consistent with these data, infection with the enteropathogenic bacteria Citrobacter rodentium, resulted in reduced innate inflammatory cell recruitment and increased bacterial colonization in the colons of il36r-/- mice. Il36r-/- mice also exhibited altered T helper cell responses in this model, with enhanced Th17 and reduced Th1 responses, demonstrating that IL-36R signaling also regulates intestinal mucosal T-cell responses. These data identify a novel role for IL-36 signaling in colonic inflammation and indicate that the IL-36R pathway may represent a novel target for therapeutic intervention in IBD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26813344     DOI: 10.1038/mi.2015.134

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  41 in total

Review 1.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

2.  Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis.

Authors:  Shuo Yang; Bingwei Wang; Fiachra Humphries; Ruaidhri Jackson; Marc E Healy; Ronan Bergin; Gabriella Aviello; Barry Hall; Deirdre McNamara; Trevor Darby; Aoife Quinlan; Fergus Shanahan; Silvia Melgar; Padraic G Fallon; Paul N Moynagh
Journal:  Nat Immunol       Date:  2013-07-28       Impact factor: 25.606

Review 3.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

4.  IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells.

Authors:  Solenne Vigne; Gaby Palmer; Praxedis Martin; Céline Lamacchia; Deborah Strebel; Emiliana Rodriguez; Maria L Olleros; Dominique Vesin; Irene Garcia; Francesca Ronchi; Federica Sallusto; John E Sims; Cem Gabay
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

5.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.

Authors:  Luigi Tortola; Esther Rosenwald; Brian Abel; Hal Blumberg; Matthias Schäfer; Anthony J Coyle; Jean-Christoph Renauld; Sabine Werner; Jan Kisielow; Manfred Kopf
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

Review 6.  Biology of IL-36 cytokines and their role in disease.

Authors:  Mark S Gresnigt; Frank L van de Veerdonk
Journal:  Semin Immunol       Date:  2013-12-17       Impact factor: 11.130

7.  The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium.

Authors:  Carola T Murphy; Lindsay J Hall; Grainne Hurley; Aoife Quinlan; John MacSharry; Fergus Shanahan; Kenneth Nally; Silvia Melgar
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

Review 8.  New drug therapies on the horizon for IBD.

Authors:  Clémentine Perrier; Paul Rutgeerts
Journal:  Dig Dis       Date:  2012-10-11       Impact factor: 2.404

Review 9.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Authors:  Wei Liao; Jian-Xin Lin; Warren J Leonard
Journal:  Immunity       Date:  2013-01-24       Impact factor: 31.745

Review 10.  Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.

Authors:  Toshifumi Hibi; Nagamu Inoue; Haruhiko Ogata; Makoto Naganuma
Journal:  J Gastroenterol       Date:  2003-03       Impact factor: 7.527

View more
  42 in total

Review 1.  Interleukin 30 to Interleukin 40.

Authors:  Jovani Catalan-Dibene; Laura L McIntyre; Albert Zlotnik
Journal:  J Interferon Cytokine Res       Date:  2018-10       Impact factor: 2.607

Review 2.  IL-34, IL-36 and IL-38 in colorectal cancer-key immunoregulators of carcinogenesis.

Authors:  Shisan Bao; Rong Hu; Brett D Hambly
Journal:  Biophys Rev       Date:  2020-07-07

3.  Long non-coding RNA Mirt2 interacts with long non-coding RNA IFNG-AS1 to regulate ulcerative colitis.

Authors:  Chenyang Li; Lujia Cui; Siqiong Li; Minrui Li; Xinpu Miao
Journal:  Exp Ther Med       Date:  2020-09-01       Impact factor: 2.447

4.  Regulation of the Peptidoglycan Amidase PGLYRP2 in Epithelial Cells by Interleukin-36γ.

Authors:  Glen M Scholz; Jacqueline E Heath; Jiamin Aw; Eric C Reynolds
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

5.  IL-36R signaling integrates innate and adaptive immune-mediated protection against enteropathogenic bacteria.

Authors:  Vu L Ngo; Hirohito Abo; Michal Kuczma; Edyta Szurek; Nora Moore; Oscar Medina-Contreras; Asma Nusrat; Didier Merlin; Andrew T Gewirtz; Leszek Ignatowicz; Timothy L Denning
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-21       Impact factor: 11.205

6.  A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage.

Authors:  Vu L Ngo; Hirohito Abo; Estera Maxim; Akihito Harusato; Duke Geem; Oscar Medina-Contreras; Didier Merlin; Andrew T Gewirtz; Asma Nusrat; Timothy L Denning
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-14       Impact factor: 11.205

7.  Opposing Effects of IL-1Ra and IL-36Ra on Innate Immune Response to Pseudomonas aeruginosa Infection in C57BL/6 Mouse Corneas.

Authors:  Nan Gao; Rao Me; Chenyang Dai; Berhane Seyoum; Fu-Shin X Yu
Journal:  J Immunol       Date:  2018-06-11       Impact factor: 5.422

Review 8.  Interleukin-36: Structure, Signaling and Function.

Authors:  Li Zhou; Viktor Todorovic
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 10.  The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19?

Authors:  Xiaofang Wang; Panpan Yi; Yuejin Liang
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.